Avita Medical (RCEL) Q3 2026 earnings review
Avita Medical sales jump and remove its cash warning
Avita Medical, the maker of the RECELL spray-on skin device for burn patients, accelerated its sales recovery and cleared its cash crunch. Third-quarter revenue rose 20% from the second quarter to $26 million as hospitals ordered more RECELL and Cohealyx wound dressings, while flat operating spending cut cash burn to $0.6 million. Chief executive Cary Vance raised the full-year sales outlook to $92–94 million, which leaves fourth-quarter sales roughly unchanged from the third quarter at about $26 million.
| Revenue | $26.1M +53% from a year ago, +20% from Q2 |
|---|---|
| Gross margin | 84.0% +2.7 percentage points from a year ago |
| Net cash use | $0.6M down from $3.2M last quarter |
| Full-year revenue outlook | Raised $5.5M middle of the range: $93M (+30%) |
⚖️ Verdict: 🟢 Bullish
The story got much better because the company removed its going-concern survival warning and Medicare finalized permanent national doctor pay rates for 2027. Passing $85 million in twelve-month sales let finance chief David O'Toole draw a final $10 million loan tranche after the quarter closed, doubling cash on hand to about $21 million by our math. One caution: shrinking inventory and $4 million of unpaid employee bonus accruals since year-end did much of the work to lower cash burn.
The question now is whether Avita can generate cash in the fourth quarter and first quarter from product sales alone rather than balance-sheet timing. If hospital ordering beats the flat fourth-quarter sales plan, operating cash will cover year-end bonus payouts and a $3 million partner payment; if sales level off, cash burn will return in early 2027. Fourth-quarter revenue and the year-end cash balance will settle it.
🐂 Bull Case
Avita Removed Its Going-Concern Warning and Unlocked $10 Million
For the past two quarters, Avita Medical carried an official warning in its filings that its cash might not last a year. Because of that risk, the wound-care group had to list its entire loan from Perceptive Advisors as due within twelve months, and it needed $85 million in twelve-month sales before March 2027 to unlock its last $10 million loan tranche.
Third-quarter sales pushed twelve-month revenue past the $85 million mark a half-year early, and the US company drew the $10 million after the quarter closed. "Based on our improved operating performance and liquidity, management concluded that the substantial doubt about our ability to continue as a going concern has been alleviated," finance chief David O'Toole said. Avita also moved the $45.5 million loan balance back to long-term debt.
This removes the immediate risk of a forced stock sale. With $10.5 million in cash at the end of September plus the new $10 million loan draw, Avita starts the fourth quarter with about $20.5 million on hand by our math, well above its $5 million loan minimum.
What to watch: the year-end cash balance in the annual report. Holding cash near $20 million before any acquisition payments would confirm the balance sheet is stable.
RECELL Sales Accelerated and Gross Margin Reached 84%
Avita's main product is RECELL, a device that turns a small sample of a burn patient's own skin into a spray that helps wounds heal. After regional Medicare payment delays hurt sales in 2025, chief executive Cary Vance said in the spring that doctors were ordering again now that all seven regional Medicare contractors had published payment rates.
That recovery sped up in the third quarter, and high-margin RECELL sales lifted the company's overall profitability despite growing sales of lower-margin partner products.
- US RECELL revenue: $22.4 million, up about 20% from the second quarter
- Cohealyx revenue (a collagen wound dressing Avita distributes): $2.1 million, up about 21% from the second quarter
- RECELL-only gross margin: 88.4%, up 4.8 percentage points from a year ago
- Total gross margin: 84.0%, as cost of sales fell 2.7 percentage points of revenue from a year ago
Because RECELL makes up 86% of total sales and carries an 88.4% margin, its manufacturing gains outweighed the 50% revenue split Avita pays its partner on Cohealyx. What to watch: fourth-quarter US RECELL sales against this quarter's $22.4 million, which will show if hospital ordering keeps growing when the full-year outlook allows for a flat quarter.
Flat Operating Spending Cut Cash Burn to $600,000
Vance has focused on keeping quarterly operating costs steady at about $24.6 million since reorganization cuts last year. In the third quarter, Avita kept total operating expenses at $24.6 million, unchanged from the second quarter and up 7% from a year ago while revenue grew 53%.
By our math, operating expenses dropped by 40.9 percentage points of revenue from a year ago, to 94.1%. Sales and marketing costs fell 18.7 points to 52.0% of revenue even after paying higher sales commissions, general and administrative overhead fell 18.2 points to 24.2%, and research and development fell 4.0 points to 18.0%. That cost control cut quarterly net cash use to $0.6 million, down from $3.2 million in the second quarter and $9.9 million in the first.
What to watch: fourth-quarter operating expenses. Keeping spending near $24.6 million when annual sales bonuses close out would allow revenue growth to flow straight to the bottom line.
Medicare Finalized National Doctor Pay Rates for 2027
Until now, seven regional Medicare contractors set their own payment rates for doctors using RECELL, a patchwork that caused billing confusion and a sales drop in 2025. On November 4, 2026, the Centers for Medicare & Medicaid Services "finalized national physician payment values and simplified billing codes for RECELL procedures, effective January 1, 2027", the company said.
Setting one national payment schedule removes regional price differences and replaces temporary local decisions with permanent national rules. What to watch: first-quarter 2027 RECELL sales, which will show whether the switch to the simplified billing codes raises doctor usage without new billing delays.
🐻 Bear Case
Unpaid Bonus Accruals and Inventory Drops Helped Cash Burn
Vance said "disciplined expense management contributed to a substantial improvement in cash use", and Avita repeated its plan for "achieving cash flow breakeven in the fourth quarter of 2026". While the operating loss shrank, the income statement and balance sheet show that timing differences did much of the work to get cash burn down to $0.6 million.
Avita still posted an operating loss of $2.6 million and paid $1.5 million in interest expense during the third quarter. Even after adding back roughly $2.6 million in non-cash stock compensation and depreciation from the prior quarter's run rate, the business still burned about $1.5 million before balance-sheet shifts by our math. Over the first nine months of 2026, accrued wages and benefits rose by $3.7 million to $11.5 million as the company recorded employee commissions and annual incentives it has not yet paid out in cash, while inventory fell by $2.1 million to $4.8 million.
Because the full-year outlook points to $24.9–26.9 million in fourth-quarter sales — roughly unchanged from the third quarter's $26.1 million — revenue growth alone will not close the remaining operating loss in the fourth quarter. Furthermore, Avita commonly pays out accrued annual bonuses in the first quarter, which caused cash burn to jump to $9.9 million in the first quarter of 2026.
What to watch: the full cash flow statement in the third-quarter filing and first-quarter 2027 cash use. If fourth-quarter breakeven relies on shrinking inventory further, cash burn will return when bonuses and supplier bills come due.
PermeaDerm Sales Stalled and Its Margin Split Narrowed
To sell more than just RECELL to burn centres, Avita distributes two partner wound dressings: Cohealyx and PermeaDerm, a biosynthetic wound matrix made by Stedical Scientific. In August, Avita reported study data for PermeaDerm "demonstrating comparable clinical outcomes to allograft while reducing product costs by 70% and preparation time by 95.7%".
Despite that clinical readout, PermeaDerm revenue stayed at $0.6 million in the third quarter, unchanged from the second quarter and only 2% of company sales. Meanwhile, the release stated that Avita now keeps "up to 55%" of the average sales price on PermeaDerm, down from the 60% share reported in prior quarters, following an August contract change that let Stedical sell directly in US markets Avita does not cover.
What to watch: fourth-quarter PermeaDerm sales. Another quarter at $0.6 million after the August clinical study would show that hospitals are slow to adopt the third product in Avita's bundle.
Risks this quarter didn't answer
Three standing concerns from last quarter could not be tested from the earnings release alone and depend on the conference call, the quarterly filing, or January execution.
- January 2027 billing code switch: while Medicare finalized the new RECELL codes, hospitals and regional contractors still must update their billing systems on January 1 without repeating the 2025 claims delays; Q1 2027 revenue will test this.
- Hospital committee backlog for Cohealyx: the release did not update the count of hospital value analysis committee (VAC) reviews or approvals, which sat near 55 active reviews last quarter; call remarks will show if the pipeline is refilling.
- The $3.0 million contingent payment: the balance sheet still carries a $3.0 million current contingent liability due to Cohealyx partner Regenity by January 2027; the filing will show whether this cash outflow hits in Q4 2026 or Q1 2027.
💲 Other KPIs
The net loss shrank by more than half from $13.2 million ($0.46 per share) a year ago and narrowed from $7.7 million in Q2. Results included a $2.1 million non-cash charge from revaluing lender warrants; excluding that one-off accounting charge, the loss was $4.1 million by our math.
Inventory fell 9.2% from the second quarter and is down 30.6% from $6.9 million at the end of 2025, releasing cash as sales grew. Accounts receivable — money hospitals owe for delivered products — rose 13.8% from year-end to $10.3 million, growing much slower than revenue.
The weighted-average share count rose 8.7% from 28.4 million a year ago due to last August's stock sale and lender share grants, but grew less than 0.4% from the second quarter. Unlocking the $10 million credit line avoided new share dilution this quarter.
🔮 Guidance
Raised. The wound-care maker lifted the middle of its full-year sales plan by $5.5 million to $93 million, or about 30% growth over 2025, following a $5.0 million raise last quarter. That leaves $24.9–26.9 million for Q4 — up 47% from last year's weak fourth quarter at the middle of the range, but down 0.7% from Q3 by our math.
Unchanged. Avita still plans to stop burning cash in the fourth quarter, compared with $0.6 million of net cash use in Q3 and $5.1 million in Q4 last year. Because the sales plan points to roughly flat revenue in Q4 at the middle of the range, reaching breakeven depends on keeping expenses flat and avoiding working-capital outflows.
New. The US company expects gross margin on its RECELL skin-spray products alone to stay between 86% and 90% over the coming quarters, right in line with Q3's 88.4% and above Q2's 86.0%. Total company gross margin will sit below that band because Cohealyx and PermeaDerm carry 50% to 55% partner price splits.
❓ Key Questions
Why does the Q4 plan point to flat sequential sales?
After revenue grew 20% from the second quarter to $26.1 million in Q3, the raised full-year outlook implies $24.9–26.9 million for Q4. Investors need to know whether management sees year-end hospital budget limits or is simply setting a cautious bar.
When will Avita pay the $3 million Cohealyx milestone?
The balance sheet carries a $3.0 million current contingent liability due to Cohealyx partner Regenity by early January 2027. Whether that cash leaves in December or January determines whether fourth-quarter net cash flow is positive.
How do the finalized 2027 Medicare rates compare to 2026?
Medicare finalized national doctor payment rates for RECELL starting January 1, 2027, but the release did not give the dollar figures. Management needs to state whether the national rate is higher or lower than the average of the seven current regional rates.
Why did Avita's price share on PermeaDerm drop to 55%?
In prior quarters, the company said it kept 60% of the average sales price on PermeaDerm; this release says it receives 'up to 55%'. Management should explain what triggered the lower split and why quarterly sales stayed flat at $0.6 million after positive trial data.